• News

Dr. C. Warren Olanow: “FDA Clears Enteral Suspension (Duopa) for Parkinson's”

  • Medscape
  • New York, NY
  • (January 12, 2015)

The US Food and Drug Administration (FDA) has approved carbidopa/levodopa enteral suspension (Duopa, AbbVie) for the treatment of motor fluctuations in patients with advanced Parkinson's disease, according to a company news release. The approval was based on a 12-week, phase 3, double-blind, multicenter trial that compared the efficacy and safety of the enteral suspension with those of oral, immediate-release (IR) carbidopa-levodopa tablets in 71 patients with advanced PD. The trial was led by C. Warren Olanow, MD, professor, Department of Neurology and Department of Neuroscience, the Icahn School of Medicine at Mount Sinai, New York, New York. Learn more